Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model

Objective. To study pharmacodynamics of meropenem alone and in combination with avibactam in an in vitro dynamic model; to evaluate effectiveness of meropenem against K. pneumoniae strains producing and not producing carbapenemases; to study impact of bacterial inoculum on meropenem activity and it...

Full description

Saved in:
Bibliographic Details
Main Authors: Strukova E.N., golikova-mv.
Format: Article
Language:Russian
Published: Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy 2025-03-01
Series:Клиническая микробиология и антимикробная химиотерапия
Subjects:
Online Access:https://cmac-journal.ru/publication/2025/1/cmac-2025-t27-n1-p33/cmac-2025-t27-n1-p33.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849423797421080576
author Strukova E.N.
golikova-mv.
author_facet Strukova E.N.
golikova-mv.
author_sort Strukova E.N.
collection DOAJ
description Objective. To study pharmacodynamics of meropenem alone and in combination with avibactam in an in vitro dynamic model; to evaluate effectiveness of meropenem against K. pneumoniae strains producing and not producing carbapenemases; to study impact of bacterial inoculum on meropenem activity and its effects. Materials and Methods. K. pneumoniae producing KPC and OXA-48 carbapenemases and non-producing strains were exposed to meropenem or its combination with avibactam (carbapenemase-producing strains only) in a modified in vitro hollow-fiber infection model (pneumoniae) simulating human pharmacokinetics of drugs administrated thrice daily for 5 days. The antimicrobial effect against the total population of K. pneumoniae was evaluated at different starting bacterial inocula (106 and 108 CFU/ml) by plating the samples on the agar media. Results. In the hollow-fiber infection model, the effect of meropenem was bactericidal for carbapenemase non-producing K. pneumoniae with MICs 2–4 mg/L, while carbapenemase-producing strains with comparable MICs of meropenem predominantly demonstrated rapid regrowth at both high and low starting inocula. The addition of avibactam led to an increased effect of meropenem and a decrease in the number of bacterial cells of all three carbapenemase-producing K. pneumoniae at both starting inocula. Conclusions. Based on meropenem susceptibility data of K. pneumoniae without checking the ability to carbapenemase production it is impossible to guarantee a successful outcome of carbapenem therapy with both low (imitation of mild infection) and high (imitation of severe infection) inocula. Addition of avibactam significantly enhanced the effect of meropenem on all carbapenemase-producing strains.
format Article
id doaj-art-e516db00b2eb4705b0a49abadc2b0e20
institution Kabale University
issn 1684-4386
2686-9586
language Russian
publishDate 2025-03-01
publisher Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
record_format Article
series Клиническая микробиология и антимикробная химиотерапия
spelling doaj-art-e516db00b2eb4705b0a49abadc2b0e202025-08-20T03:30:28ZrusInterregional Association for Clinical Microbiology and Antimicrobial ChemotherapyКлиническая микробиология и антимикробная химиотерапия1684-43862686-95862025-03-01271334110.36488/cmac.2025.1.33-41cmac-2025-t27-n1-p33Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic modelStrukova E.N.0golikova-mv.1Gause Institute of New Antibiotics, Moscow, RussiaGause Institute of New Antibiotics, Moscow, RussiaObjective. To study pharmacodynamics of meropenem alone and in combination with avibactam in an in vitro dynamic model; to evaluate effectiveness of meropenem against K. pneumoniae strains producing and not producing carbapenemases; to study impact of bacterial inoculum on meropenem activity and its effects. Materials and Methods. K. pneumoniae producing KPC and OXA-48 carbapenemases and non-producing strains were exposed to meropenem or its combination with avibactam (carbapenemase-producing strains only) in a modified in vitro hollow-fiber infection model (pneumoniae) simulating human pharmacokinetics of drugs administrated thrice daily for 5 days. The antimicrobial effect against the total population of K. pneumoniae was evaluated at different starting bacterial inocula (106 and 108 CFU/ml) by plating the samples on the agar media. Results. In the hollow-fiber infection model, the effect of meropenem was bactericidal for carbapenemase non-producing K. pneumoniae with MICs 2–4 mg/L, while carbapenemase-producing strains with comparable MICs of meropenem predominantly demonstrated rapid regrowth at both high and low starting inocula. The addition of avibactam led to an increased effect of meropenem and a decrease in the number of bacterial cells of all three carbapenemase-producing K. pneumoniae at both starting inocula. Conclusions. Based on meropenem susceptibility data of K. pneumoniae without checking the ability to carbapenemase production it is impossible to guarantee a successful outcome of carbapenem therapy with both low (imitation of mild infection) and high (imitation of severe infection) inocula. Addition of avibactam significantly enhanced the effect of meropenem on all carbapenemase-producing strains.https://cmac-journal.ru/publication/2025/1/cmac-2025-t27-n1-p33/cmac-2025-t27-n1-p33.pdfmeropenemavibactamklebsiella pneumoniaecarbapenemasesin vitro dynamic model
spellingShingle Strukova E.N.
golikova-mv.
Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
Клиническая микробиология и антимикробная химиотерапия
meropenem
avibactam
klebsiella pneumoniae
carbapenemases
in vitro dynamic model
title Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
title_full Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
title_fullStr Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
title_full_unstemmed Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
title_short Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
title_sort pharmacodynamics of meropenem and meropenem combined with avibactam against klebsiella pneumoniae in an in vitro dynamic model
topic meropenem
avibactam
klebsiella pneumoniae
carbapenemases
in vitro dynamic model
url https://cmac-journal.ru/publication/2025/1/cmac-2025-t27-n1-p33/cmac-2025-t27-n1-p33.pdf
work_keys_str_mv AT strukovaen pharmacodynamicsofmeropenemandmeropenemcombinedwithavibactamagainstklebsiellapneumoniaeinaninvitrodynamicmodel
AT golikovamv pharmacodynamicsofmeropenemandmeropenemcombinedwithavibactamagainstklebsiellapneumoniaeinaninvitrodynamicmodel